ID   PC346Enza
AC   CVCL_RA54
DR   Wikidata; Q54938577
RX   PubMed=24200698;
CC   Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; MDV-3100).
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4883 ! PC-346C
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 29-06-23; Version: 6
//
RX   PubMed=24200698; DOI=10.1016/j.ejca.2013.09.026;
RA   van Soest R.J., van Royen M.E., de Morree E.S., Moll J.M., Teubel W.J.,
RA   Wiemer E.A.C., Mathijssen R.H.J., de Wit R., van Weerden W.M.;
RT   "Cross-resistance between taxanes and new hormonal agents abiraterone
RT   and enzalutamide may affect drug sequence choices in metastatic
RT   castration-resistant prostate cancer.";
RL   Eur. J. Cancer 49:3821-3830(2013).
//